Display options
Cite
Roberts JK, Moore CD, Romero EG, et al. Regulation of CYP3A genes by glucocorticoids in human lung cells. F1000Res. 2013;2:173doi: 10.12688/f1000research.2-173.v2.
Roberts, J. K., Moore, C. D., Romero, E. G., Ward, R. M., Yost, G. S., & Reilly, C. A. (2013). Regulation of CYP3A genes by glucocorticoids in human lung cells. F1000Research, 2173. https://doi.org/10.12688/f1000research.2-173.v2
Roberts, Jessica K, et al. "Regulation of CYP3A genes by glucocorticoids in human lung cells." F1000Research vol. 2 (2013): 173. doi: https://doi.org/10.12688/f1000research.2-173.v2
Roberts JK, Moore CD, Romero EG, Ward RM, Yost GS, Reilly CA. Regulation of CYP3A genes by glucocorticoids in human lung cells. F1000Res. 2013 Aug 13;2:173. doi: 10.12688/f1000research.2-173.v2. eCollection 2013. PMID: 24555085; PMCID: PMC3869485.
Copy Download .nbib Format: NLM
Share it on

F1000Res. 2013 Aug 13;2:173. doi: 10.12688/f1000research.2-173.v2. eCollection 2013.

Regulation of CYP3A genes by glucocorticoids in human lung cells.

F1000Research

Jessica K Roberts, Chad D Moore, Erin G Romero, Robert M Ward, Garold S Yost, Christopher A Reilly

Affiliations

  1. Department of Pharmacology and Toxicology, College of Pharmacy, University of Utah, Salt Lake City UT, 84112, USA.
  2. Department of Pediatrics, School of Medicine, University of Utah, Salt Lake City UT, 84108, USA.

PMID: 24555085 PMCID: PMC3869485 DOI: 10.12688/f1000research.2-173.v2

Abstract

Inhaled glucocorticoids are the first-line treatment for patients with persistent asthma.  However, approximately thirty percent of patients exhibit glucocorticoid insensitivity, which may involve excess metabolic clearance of the glucocorticoids by CYP3A enzymes in the lung.  CYP3A4, 3A5, and 3A7 enzymes metabolize glucocorticoids, which in turn induce CYP3A genes.  However, the mechanism of CYP3A5 mRNA regulation by glucocorticoids in lung cells has not been determined.  In hepatocytes, glucocorticoids bind to the glucocorticoid receptor (GR), which induces the expression of the constitutive androstane receptor or pregnane X receptor; both of which bind to the retinoid X receptor alpha, leading to the induction of CYP3A4, 3A5, and 3A7.  There is also evidence to suggest a direct induction of CYP3A5 by GR activation in liver cells. In this study, these pathways were evaluated as the mechanism for CYP3A5 mRNA induction by glucocorticoids in freshly isolated primary tracheal epithelial, adenocarcinomic human alveolar basal epithelial (A549), immortalized bronchial epithelial (BEAS-2B), primary normal human bronchial/tracheal epithelial (NHBE), primary small airway epithelial (SAEC), and primary lobar epithelial lung cells. In A549 cells, beclomethasone 17-monopropionate ([M1]) induced CYP3A5 mRNA through the glucocorticoid receptor. CYP3A5 mRNA induction by five different glucocorticoids was attenuated by inhibiting the glucocorticoid receptor using ketoconazole, and for beclomethasone dipropionate, using siRNA-mediated knock-down of the glucocorticoid receptor. The constitutive androstane receptor was not expressed in lung cells. SAEC cells, a primary lung cell line, expressed CYP3A5, but CYP3A5 mRNA was not induced by glucocorticoid treatment despite evaluating a multitude of cell culture conditions. None of the other lung cells expressed CYP3A4, 3A5 or 3A7 mRNA. These studies demonstrate that CYP3A5 mRNA is induced by glucocorticoids in A549 cells via the glucocorticoid receptor, but that additional undefined regulatory processes exist in primary lung cells.

References

  1. Clin Chest Med. 2006 Mar;27(1):119-32, vii - PubMed
  2. Drug Metab Dispos. 2006 Jun;34(6):1035-40 - PubMed
  3. J Allergy Clin Immunol. 2003 Jan;111(1):3-22; quiz 23 - PubMed
  4. Endocr Rev. 2002 Oct;23(5):687-702 - PubMed
  5. Nat Genet. 2001 Apr;27(4):383-91 - PubMed
  6. Biochimie. 2010 Mar;92(3):292-306 - PubMed
  7. J Biol Chem. 2003 Jul 25;278(30):28312-23 - PubMed
  8. Annu Rev Pharmacol Toxicol. 2002;42:1-23 - PubMed
  9. Drug Metab Dispos. 1995 Jan;23(1):137-42 - PubMed
  10. MMWR Recomm Rep. 2003 Mar 28;52(RR-6):1-8 - PubMed
  11. J Pharmacol Exp Ther. 2003 Feb;304(2):745-52 - PubMed
  12. J Clin Pharmacol. 1990 Apr;30(4):303-10 - PubMed
  13. Toxicol Sci. 2011 Apr;120(2):381-91 - PubMed
  14. Mol Pharmacol. 2006 Jul;70(1):329-39 - PubMed
  15. Eur J Biochem. 1997 Jul 15;247(2):625-34 - PubMed
  16. Eur Respir J. 2008 Jan;31(1):143-78 - PubMed
  17. Drug Metab Dispos. 2013 Feb;41(2):379-89 - PubMed
  18. Mol Pharmacol. 1996 Jan;49(1):63-72 - PubMed
  19. Mol Carcinog. 1997 Oct;20(2):224-30 - PubMed
  20. Drugs. 1973;6(2):84-93 - PubMed
  21. Drug Metab Dispos. 2003 Jun;31(6):755-61 - PubMed
  22. J Allergy Clin Immunol. 2007 Nov;120(5 Suppl):S94-138 - PubMed
  23. J Clin Pharmacol. 2007 May;47(5):566-78 - PubMed
  24. Drug Metab Rev. 2010 Nov;42(4):621-35 - PubMed
  25. J Pharmacol Exp Ther. 2013 May;345(2):308-16 - PubMed
  26. Pharmacogenetics. 1994 Feb;4(1):11-20 - PubMed
  27. Chem Biol Interact. 2005 Jan 15;151(2):53-62 - PubMed
  28. Arch Toxicol. 2003 Mar;77(3):145-9 - PubMed
  29. Drug Metab Dispos. 2012 Oct;40(10):1953-65 - PubMed

Publication Types

Grant support